Literature DB >> 1804785

Quinolones in the treatment of lower respiratory tract infections caused by intracellular pathogens.

C Chidiac1, Y Mouton.   

Abstract

Intracellular pathogens are inhibited to varying degrees, depending upon the strain of the organism and the quinolone tested. Quinolones achieve levels in the lower respiratory tract that equal or exceed serum concentrations, and they also achieve good intracellular concentrations. Experimental models of intracellular infection have demonstrated the efficacy of ciprofloxacin, difloxacin, fleroxacin, ofloxacin and pefloxacin. Animal models of experimental legionellosis have confirmed in vivo their efficacy in this field. Thus, quinolones appear to be a safe and efficacious alternative treatment in lower respiratory tract infection (LRTI) due to intracellular pathogens. Considering the in vitro and experimental studies, quinolones should play an important role in the treatment of LRTI caused by intracellular pathogens, and prospective controlled studies are strongly recommended.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1804785     DOI: 10.1007/BF01715829

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  32 in total

1.  Ciprofloxacin in the treatment of legionellosis in critically ill patients including those cases unresponsive to erythromycin.

Authors:  K E Unertl; F P Lenhart; H Forst; G Vogler; V Wilm; W Ehret; G Ruckdeschel
Journal:  Am J Med       Date:  1989-11-30       Impact factor: 4.965

2.  [Evaluation of ciprofloxacin versus amoxicillin + clavulanic acid or erythromycin for the empiric treatment of community-acquired pneumonia].

Authors:  Y Mouton; C Beuscart; O Leroy; F Ajana; J Charrel
Journal:  Pathol Biol (Paris)       Date:  1991-01

3.  Cellular uptake, localization and activity of fluoroquinolones in uninfected and infected macrophages.

Authors:  M B Carlier; B Scorneaux; A Zenebergh; J F Desnottes; P M Tulkens
Journal:  J Antimicrob Chemother       Date:  1990-10       Impact factor: 5.790

4.  Penetration of ofloxacin into human lung tissue following a single oral dose of 200 milligrams.

Authors:  F Serour; M Dan; A Gorea; A Yellin; Y Lieberman; S A Berger
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

5.  Comparative susceptibility of Mycoplasma pneumoniae to erythromycin, ciprofloxacin, and lomefloxacin.

Authors:  G H Cassell; K B Waites; M S Pate; K C Canupp; L B Duffy
Journal:  Diagn Microbiol Infect Dis       Date:  1989 Sep-Oct       Impact factor: 2.803

6.  The penetration of ofloxacin into lung tissue.

Authors:  W J Wijnands; T B Vree; A M Baars; J C Hafkenscheid; B E Kohler; C L van Herwaarden
Journal:  J Antimicrob Chemother       Date:  1988-09       Impact factor: 5.790

7.  The effect of ofloxacin on the intracellular growth of Legionella pneumophila in guinea pig alveolar phagocytes.

Authors:  R B Fitzgeorge; A S Featherstone; A Baskerville
Journal:  J Antimicrob Chemother       Date:  1988-09       Impact factor: 5.790

8.  In vitro susceptibility of Coxiella burnetii to antibiotics, including several quinolones.

Authors:  M R Yeaman; L A Mitscher; O G Baca
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

9.  Diffusion of ofloxacin into human lung tissue.

Authors:  L Couraud; J B Fourtillan; M C Saux; A Bryskier; M Vincent du Laurier
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 10.  [Treatment of legionellosis with ofloxacin in kidney transplanted patients. Lack of interaction with cyclosporin A].

Authors:  A Wynckel; O Toupance; J P Melin; C David; S Lavaud; T Wong; D Lamiable; J Chanard
Journal:  Presse Med       Date:  1991-02-23       Impact factor: 1.228

View more
  1 in total

Review 1.  Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.

Authors:  J A Balfour; P A Todd; D H Peters
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.